

# Hann-Chorng Kuo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1036349/publications.pdf>

Version: 2024-02-01

400  
papers

9,844  
citations

38660

50  
h-index

71532

76  
g-index

412  
all docs

412  
docs citations

412  
times ranked

3799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. International Journal of Urology, 2009, 16, 597-615.	0.5	197
2	Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology, 2004, 63, 868-872.	0.5	185
3	Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU International, 2009, 104, 657-661.	1.3	166
4	Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection. European Urology, 2009, 56, 700-707.	0.9	163
5	Intravesical Botulinum Toxin A Injections Plus Hydrodistension Can Reduce Nerve Growth Factor Production and Control Bladder Pain in Interstitial Cystitis. Urology, 2007, 70, 463-468.	0.5	145
6	Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology, 2005, 66, 1005-1009.	0.5	144
7	Comparison of Effectiveness of Detrusor, Suburothelial and Bladder Base Injections of Botulinum Toxin A for Idiopathic Detrusor Overactivity. Journal of Urology, 2007, 178, 1359-1363.	0.2	136
8	Botulinum A Toxin Urethral Injection for the Treatment of Lower Urinary Tract Dysfunction. Journal of Urology, 2003, 170, 1908-1912.	0.2	130
9	Prostate botulinum A toxin injection an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology, 2005, 65, 670-674.	0.5	124
10	Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology, 2005, 66, 94-98.	0.5	123
11	Clinical guidelines for interstitial cystitis/bladder pain syndrome. International Journal of Urology, 2020, 27, 578-589.	0.5	122
12	Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU International, 2009, 104, 1476-1481.	1.3	118
13	Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU International, 2011, 108, E136-41.	1.3	115
14	Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome. European Urology, 2010, 58, 919-926.	0.9	113
15	Urinary Nerve Growth Factor Level Could be a Potential Biomarker for Diagnosis of Overactive Bladder. Journal of Urology, 2008, 179, 2270-2274.	0.2	108
16	Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU International, 2009, 103, 1668-1672.	1.3	101
17	Differences in Mast Cell Infiltration, E-cadherin, and Zonula Occludens-1 Expression Between Patients With Overactive Bladder and Interstitial Cystitis/Bladder Pain Syndrome. Urology, 2012, 80, 225.e13-225.e18.	0.5	100
18	Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study. European Urology, 2014, 65, 1117-1124.	0.9	100

#	ARTICLE	IF	CITATIONS
19	Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. International Journal of Urology, 2016, 23, 542-549.	0.5	100
20	Intravesical botulinum toxinâ€A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment â€“ A prospective, multicenter, randomized, doubleâ€blind, placeboâ€controlled clinical trial. Neurourology and Urodynamics, 2016, 35, 609-614.	0.8	99
21	Urinary Nerve Growth Factor Levels Are Increased in Patients with Bladder Outlet Obstruction with Overactive Bladder Symptoms and Reduced After Successful Medical Treatment. Urology, 2008, 72, 104-108.	0.5	95
22	Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology, 2003, 61, 550-554.	0.5	94
23	Preliminary Results of Suburothelial Injection of Botulinum A Toxin in the Treatment of Chronic Interstitial Cystitis. Urologia Internationalis, 2005, 75, 170-174.	0.6	93
24	Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU International, 2010, 106, 1681-1685.	1.3	92
25	Increased Pro-Inflammatory Cytokines, C-Reactive Protein and Nerve Growth Factor Expressions in Serum of Patients with Interstitial Cystitis/Bladder Pain Syndrome. PLoS ONE, 2013, 8, e76779.	1.1	91
26	Increased Cell Apoptosis of Urothelium Mediated by Inflammation in Interstitial Cystitis/Painful Bladder Syndrome. Urology, 2012, 79, 484.e7-484.e13.	0.5	90
27	Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial. Journal of Urology, 2014, 192, 1743-1749.	0.2	88
28	Elevation of serum câ€reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourology and Urodynamics, 2011, 30, 417-420.	0.8	85
29	Possible pathophysiology of ketamineâ€related cystitis and associated treatment strategies. International Journal of Urology, 2015, 22, 816-825.	0.5	83
30	Clinical prostate score for diagnosis of bladder outlet obstruction by prostate measurements and uroflowmetry. Urology, 1999, 54, 90-96.	0.5	80
31	Results of a randomized, doubleâ€blind, parallelâ€group, placeboâ€and activeâ€controlled, multicenter study of mirabegron, a Î²3â€adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics, 2015, 34, 685-692.	0.8	80
32	Increased Risk of Large Post-Void Residual Urine and Decreased Long-Term Success Rate After Intravesical OnabotulinumtoxinA Injection for Refractory Idiopathic Detrusor Overactivity. Journal of Urology, 2013, 189, 1804-1810.	0.2	76
33	Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology, 2006, 67, 232-236.	0.5	74
34	Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourology and Urodynamics, 2011, 30, 1242-1248.	0.8	72
35	Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?. Urology, 2006, 68, 993-997.	0.5	70
36	Recovery of Detrusor Function After Urethral Botulinum A Toxin Injection in Patients with Idiopathic Low Detrusor Contractility and Voiding Dysfunction. Urology, 2007, 69, 57-61.	0.5	70

#	ARTICLE	IF	CITATIONS
37	Increased apoptosis and suburothelial inflammation in patients with ketamine-related cystitis: a comparison with non-ulcerative interstitial cystitis and controls. <i>BJU International</i> , 2013, 112, 1156-1162.	1.3	70
38	Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. <i>International Journal of Urology</i> , 2014, 21, 34-41.	0.5	64
39	Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease. <i>International Neurourology Journal</i> , 2016, 20, S95-104.	0.5	62
40	Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin <scp>A</scp> injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. <i>BJU International</i> , 2013, 111, 638-646.	1.3	61
41	Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type-2 diabetes mellitus. <i>International Journal of Urology</i> , 2012, 19, 995-1001.	0.5	60
42	International prostate symptom score for assessing lower urinary tract dysfunction in women. <i>International Urogynecology Journal</i> , 2013, 24, 263-267.	0.7	60
43	Videourodynamic Analysis of Pathophysiology of Men with Both Storage and Voiding Lower Urinary Tract Symptoms. <i>Urology</i> , 2007, 70, 272-276.	0.5	59
44	Urodynamic Parameters for the Diagnosis of Bladder Outlet Obstruction in Women. <i>Urologia Internationalis</i> , 2004, 72, 46-51.	0.6	57
45	Satisfaction with urethral injection of Botulinum Toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. <i>Neurourology and Urodynamics</i> , 2008, 27, 793-796.	0.8	57
46	Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. <i>Neurourology and Urodynamics</i> , 2011, 30, 1525-1529.	0.8	57
47	A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2017, 198, 376-382.	0.2	56
48	Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. <i>Neurourology and Urodynamics</i> , 2010, 29, 482-487.	0.8	55
49	Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. <i>BJU International</i> , 2008, 102, 080516035452788-???	1.3	54
50	Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. <i>Neurourology and Urodynamics</i> , 2009, 28, 78-81.	0.8	53
51	Effectiveness Of Intravesical Resiniferatoxin For Anticholinergic Treatment Refractory Detrusor Overactivity Due To Nonspinal Cord Lesions. <i>Journal of Urology</i> , 2003, 170, 835-839.	0.2	52
52	Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years. <i>Urology</i> , 2002, 59, 485-489.	0.5	51
53	Urinary Nerve Growth Factor Levels in Overactive Bladder Syndrome and Lower Urinary Tract Disorders. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 862-878.	0.8	50
54	Increased Urine and Serum Nerve Growth Factor Levels in Interstitial Cystitis Suggest Chronic Inflammation Is Involved in the Pathogenesis of Disease. <i>PLoS ONE</i> , 2012, 7, e44687.	1.1	50

#	ARTICLE	IF	CITATIONS
55	Therapeutic Effect of Multiple Resiniferatoxin Intravesical Instillations in Patients With Refractory Detrusor Overactivity: A Randomized, Double-Blind, Placebo Controlled Study. <i>Journal of Urology</i> , 2006, 176, 641-645.	0.2	49
56	Urinary nerve growth factor in women with overactive bladder syndrome. <i>BJU International</i> , 2011, 107, 799-803.	1.3	49
57	Alteration of Urothelial Inflammation, Apoptosis, and Junction Protein in Patients with Various Bladder Conditions and Storage Bladder Symptoms Suggest Common Pathway Involved in Underlying Pathophysiology. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015, 7, 102-107.	0.6	49
58	Videourodynamic Studies of Women with Voiding Dysfunction. <i>Scientific Reports</i> , 2017, 7, 6845.	1.6	49
59	Urothelial Barrier Deficits, Suburothelial Inflammation and Altered Sensory Protein Expression in Detrusor Underactivity. <i>Journal of Urology</i> , 2017, 197, 197-203.	0.2	49
60	Transurethral incision of bladder neck in treatment of bladder neck obstruction in women. <i>Urology</i> , 2005, 65, 275-278.	0.5	48
61	Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis. <i>Pain Physician</i> , 2013, 16, 109-116.	0.3	47
62	Association of inflammaging (inflammation+aging) with higher prevalence of OAB in elderly population. <i>International Urology and Nephrology</i> , 2014, 46, 871-877.	0.6	45
63	Can urinary nerve growth factor be a biomarker for overactive bladder?. <i>Reviews in Urology</i> , 2010, 12, e69-77.	0.9	45
64	Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: A comparative randomized assessment of different regimens. <i>International Journal of Urology</i> , 2013, 20, 203-207.	0.5	44
65	Elevated Serum IgE May be Associated with Development of Ketamine Cystitis. <i>Journal of Urology</i> , 2014, 192, 1249-1256.	0.2	43
66	COMPARISON OF VIDEO URODYNAMIC RESULTS AFTER THE PUBOVAGINAL SLING PROCEDURE USING RECTUS FASCIA AND POLYPROPYLENE MESH FOR STRESS URINARY INCONTINENCE. <i>Journal of Urology</i> , 2001, 165, 163-168.	0.2	39
67	Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. <i>Neurourology and Urodynamics</i> , 2011, 30, 1300-1304.	0.8	39
68	Repeated Onabotulinumtoxin-A Injections Provide Better Results than Single Injection in Treatment of Painful Bladder Syndrome. <i>Pain Physician</i> , 2013, 1;16, E15-E23.	0.3	39
69	Analysis of the Pathophysiology of Lower Urinary Tract Symptoms in Patients after Prostatectomy. <i>Urologia Internationalis</i> , 2002, 68, 99-104.	0.6	38
70	Down Regulation of Vascular Endothelial Growth Factor Is Associated With Decreased Inflammation After Intravesical OnabotulinumtoxinA Injections Combined With Hydrodistention for Patients With Interstitial Cystitisâ€”Clinical Results and Immunohistochemistry Analysis. <i>Urology</i> , 2013, 82, 1452.e1-1452.e6.	0.5	38
71	Augmentation enterocystoplasty is effective in relieving refractory ketamineâ€”related bladder pain. <i>Neurourology and Urodynamics</i> , 2014, 33, 1207-1211.	0.8	38
72	Increased Urothelial Cell Apoptosis and Chronic Inflammation Are Associated with Recurrent Urinary Tract Infection in Women. <i>PLoS ONE</i> , 2013, 8, e63760.	1.1	38

#	ARTICLE	IF	CITATIONS
73	Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography. <i>International Urogynecology Journal</i> , 2009, 20, 1293-1299.	0.7	37
74	Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009, 43, 206-211.	1.4	36
75	Long-term Outcomes of Augmentation Enterocystoplasty with an Ileal Segment in Patients with Spinal Cord Injury. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 475-480.	0.8	36
76	Pathophysiology of refractory overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 177-181.	0.6	36
77	Increased Serum C-Reactive Protein Level Is Associated with Increased Storage Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia. <i>PLoS ONE</i> , 2014, 9, e85588.	1.1	36
78	Causes of Failed Urethral Botulinum Toxin A Treatment for Emptying Failure. <i>Urology</i> , 2007, 70, 763-766.	0.5	35
79	Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2018, 200, 590-596.	0.2	35
80	Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1391-F1399.	1.3	35
81	Ureteroscopic Treatment of Lower Ureteral Calculi in the Era of Extracorporeal Shock Wave Lithotripsy: From a Developing Country Point of View. <i>Journal of Urology</i> , 1993, 150, 1395-1398.	0.2	34
82	The role of serum C-reactive protein in women with lower urinary tract symptoms. <i>International Urogynecology Journal</i> , 2012, 23, 935-940.	0.7	34
83	Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. <i>PLoS ONE</i> , 2018, 13, e0198816.	1.1	34
84	Clinical symptoms are not reliable in the diagnosis of lower urinary tract dysfunction in women. <i>Journal of the Formosan Medical Association</i> , 2012, 111, 386-391.	0.8	33
85	Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action. <i>Toxins</i> , 2016, 8, 120.	1.5	33
86	Recovery of Voiding Efficiency and Bladder Function in Male Patients With Non-neurogenic Detrusor Underactivity After Transurethral Bladder Outlet Surgery. <i>Urology</i> , 2019, 123, 235-241.	0.5	33
87	Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. <i>Tzu Chi Medical Journal</i> , 2017, 29, 79.	0.4	33
88	Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. <i>Investigative and Clinical Urology</i> , 2020, 61, S33.	1.0	33
89	Reduction of cystometric bladder capacity and bladder compliance with time in patients with end-stage renal disease. <i>Journal of the Formosan Medical Association</i> , 2012, 111, 209-213.	0.8	32
90	Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention. <i>Tzu Chi Medical Journal</i> , 2017, 29, 131.	0.4	32

#	ARTICLE	IF	CITATIONS
91	Urodynamic characteristics of detrusor underactivity in women with voiding dysfunction. PLoS ONE, 2018, 13, e0198764.	1.1	32
92	Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. Scientific Reports, 2021, 11, 914.	1.6	32
93	Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician, 2013, 16, E15-23.	0.3	32
94	Effect of detrusor function on the therapeutic outcome of a suburethral sling procedure using a polypropylene sling for stress urinary incontinence in women. Scandinavian Journal of Urology and Nephrology, 2007, 41, 138-143.	1.4	31
95	Urinary Nerve Growth Factor Levels in Urinary Tract Diseases With or Without Frequency Urgency Symptoms. LUTS: Lower Urinary Tract Symptoms, 2010, 2, 88-94.	0.6	31
96	Current and potential urological applications of botulinum toxin A. Nature Reviews Urology, 2015, 12, 519-533.	1.9	31
97	Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment—A prospective clinical trial. Neurourology and Urodynamics, 2019, 38, 703-709.	0.8	31
98	Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O42-O47.	0.6	31
99	Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. BJU International, 2005, 95, 1023-1027.	1.3	30
100	Effectiveness of Urethral Injection of Botulinum A Toxin in the Treatment of Voiding Dysfunction after Radical Hysterectomy. Urologia Internationalis, 2005, 75, 247-251.	0.6	30
101	Therapeutic Satisfaction and Dissatisfaction in Patients With Spinal Cord Lesions and Detrusor Sphincter Dyssynergia Who Received Detrusor Botulinum Toxin A Injection. Urology, 2008, 72, 1056-1060.	0.5	30
102	Positioning of a Suburethral Sling at the Bladder Neck Is Associated With a Higher Recurrence Rate of Stress Urinary Incontinence. Journal of Ultrasound in Medicine, 2013, 32, 239-245.	0.8	30
103	Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder. PLoS ONE, 2014, 9, e105989.	1.1	30
104	Transurethral Incision of the bladder neck improves voiding efficiency in female patients with detrusor underactivity. International Urogynecology Journal, 2014, 25, 671-676.	0.7	30
105	Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection. Toxins, 2015, 7, 2232-2250.	1.5	30
106	Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Scientific Reports, 2020, 10, 15218.	1.6	30
107	Quality of Life after Active Urological Management of Chronic Spinal Cord Injury in Eastern Taiwan. European Urology, 1998, 34, 37-46.	0.9	29
108	Pathophysiology of Lower Urinary Tract Symptoms in Aged Men without Bladder Outlet Obstruction. Urologia Internationalis, 2000, 64, 86-92.	0.6	29

#	ARTICLE	IF	CITATIONS
109	ANATOMICAL AND FUNCTIONAL RESULTS OF PUBOVAGINAL SLING PROCEDURE USING POLYPROPYLENE MESH FOR THE TREATMENT OF STRESS URINARY INCONTINENCE. <i>Journal of Urology</i> , 2001, 166, 152-157.	0.2	29
110	Urodynamic Study and Potassium Sensitivity Test for Women with Frequency-Urgency Syndrome and Interstitial Cystitis. <i>Urologia Internationalis</i> , 2003, 71, 61-65.	0.6	29
111	Serum C-reactive Protein Levels are Associated With Residual Urgency Symptoms in Patients With Benign Prostatic Hyperplasia After Medical Treatment. <i>Urology</i> , 2011, 78, 1373-1378.	0.5	29
112	Decrease of Urinary Nerve Growth Factor but Not Brain-Derived Neurotrophic Factor in Patients with Interstitial Cystitis/Bladder Pain Syndrome Treated with Hyaluronic Acid. <i>PLoS ONE</i> , 2014, 9, e91609.	1.1	29
113	Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2014, 33, 1235-1239.	0.8	29
114	Clinical and video urodynamic characteristics of Adult women with dysfunctional voiding. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 161-165.	0.8	29
115	The Overactive Bladder Symptom Score, International Prostate Symptom Score's "Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best?. <i>International Neurourology Journal</i> , 2018, 22, 99-106.	0.5	29
116	Botulinum A Toxin Treatment of Urethral Sphincter Pseudodyssynergia in Patients with Cerebrovascular Accidents or Intracranial Lesions. <i>Urologia Internationalis</i> , 2004, 73, 156-162.	0.6	28
117	Long-Term Efficacy and Safety of Repeated Intravesical OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome. <i>Toxins</i> , 2015, 7, 4283-4293.	1.5	28
118	Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. <i>PLoS ONE</i> , 2016, 11, e0147137.	1.1	28
119	Videourodynamic results after pubovaginal sling procedure for stress urinary incontinence. <i>Urology</i> , 1999, 54, 802-806.	0.5	27
120	Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. <i>BJU International</i> , 2007, 100, 070817233103004-???	1.3	27
121	Botulinum toxin for the lower urinary tract. <i>BJU International</i> , 2010, 105, 1046-1058.	1.3	27
122	The efficacy of additive tolterodine extended release for 1 year in older men with storage symptoms and clinical benign prostatic hyperplasia. <i>Neurourology and Urodynamics</i> , 2011, 30, 568-571.	0.8	27
123	Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. <i>Neurourology and Urodynamics</i> , 2011, 30, 1541-1545.	0.8	27
124	Botulinum toxin injection for lower urinary tract dysfunction. <i>International Journal of Urology</i> , 2013, 20, 40-55.	0.5	27
125	Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 276-282.	0.8	27
126	Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy. <i>PLoS ONE</i> , 2013, 8, e76706.	1.1	27

#	ARTICLE	IF	CITATIONS
127	The Therapeutic Effects of Repeated Detrusor Injections Between 200 or 300 Units of OnabotulinumtoxinA in Chronic Spinal Cord Injured Patients. <i>Neurourology and Urodynamics</i> , 2014, 33, 129-134.	0.8	27
128	Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome—A prospective, multicenter, randomized, double-blind, placebo-controlled study. <i>Neurourology and Urodynamics</i> , 2020, 39, 1505-1514.	0.8	27
129	Videourodynamic analysis of the urethral sphincter overactivity and the poor relaxing pelvic floor muscles in women with voiding dysfunction. <i>Neurourology and Urodynamics</i> , 2017, 36, 2169-2175.	0.8	26
130	The Relationships of Urethral and Pelvic Floor Muscles and the Urethral Pressure Measurements in Women with Stress Urinary Incontinence. <i>European Urology</i> , 2000, 37, 149-155.	0.9	25
131	Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. <i>BJU International</i> , 2009, 104, 1158-1162.	1.3	25
132	Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. <i>BJU International</i> , 2010, 105, 668-672.	1.3	25
133	Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxinA injection for idiopathic detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2011, 30, 1497-1502.	0.8	25
134	High Classification of Chronic Heart Failure Increases Risk of Overactive Bladder Syndrome and Lower Urinary Tract Symptoms. <i>Urology</i> , 2012, 79, 260-265.	0.5	25
135	Urothelial Dysfunction, Suburothelial Inflammation and Altered Sensory Protein Expression in Men with Bladder Outlet Obstruction and Various Bladder Dysfunctions: Correlation with Urodynamics. <i>Journal of Urology</i> , 2016, 196, 831-837.	0.2	25
136	Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. <i>Pain Physician</i> , 2012, 15, 197-202.	0.3	25
137	Predictors of Successful First-line Antimuscarinic Monotherapy in Men With Enlarged Prostate and Predominant Storage Symptoms. <i>Urology</i> , 2013, 81, 1030-1033.	0.5	24
138	Ketamine cystitis: Its urological impact and management. <i>Urological Science</i> , 2015, 26, 153-157.	0.2	24
139	Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility. <i>Toxins</i> , 2016, 8, 82.	1.5	24
140	Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study. <i>Neurourology and Urodynamics</i> , 2016, 35, 717-723.	0.8	24
141	Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment. <i>Scientific Reports</i> , 2021, 11, 455.	1.6	24
142	Management of Lower Urinary Tract Dysfunction After Radical Hysterectomy With or Without Radiotherapy for Uterine Cervical Cancer. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 619-626.	0.8	23
143	Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxinA injections for overactive bladder syndrome—A real-life practice of 290 cases in a single center. <i>Neurourology and Urodynamics</i> , 2017, 36, 142-147.	0.8	23
144	Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. <i>International Journal of Urology</i> , 2014, 21, 49-55.	0.5	22

#	ARTICLE	IF	CITATIONS
145	Patient characteristics for different therapeutic strategies in the management ketamine cystitis. <i>Neurourology and Urodynamics</i> , 2017, 36, 687-691.	0.8	22
146	Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis. <i>PLoS ONE</i> , 2016, 11, e0151692.	1.1	22
147	Clinical Outcome and Quality of Life after Enterocystoplasty for Contracted Bladders. <i>Urologia Internationalis</i> , 1997, 58, 160-165.	0.6	21
148	Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 583-589.	0.8	20
149	OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction â€” A Randomized, Double-Blind, Placebo-Controlled Study. <i>Scientific Reports</i> , 2016, 6, 38905.	1.6	20
150	Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men â€” A comparison of men with normal tracing and bladder outlet obstruction. <i>PLoS ONE</i> , 2017, 12, e0174593.	1.1	20
151	International Consultation on Incontinence 2016; Executive summary: Urodynamic testing. <i>Neurourology and Urodynamics</i> , 2019, 38, 545-552.	0.8	20
152	Botulinum Toxin A Injection to the Bladder Neck and Urethra for Medically Refractory Lower Urinary Tract Symptoms in Men Without Prostatic Obstruction. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 950-956.	0.8	19
153	Transurethral incision of the bladder neck to treat bladder neck dysfunction and voiding dysfunction in patients with high-level spinal cord injuries. <i>Neurourology and Urodynamics</i> , 2010, 29, 748-752.	0.8	19
154	Bladder management and urological complications in patients with chronic spinal cord injuries in Taiwan. <i>Tzu Chi Medical Journal</i> , 2014, 26, 25-28.	0.4	19
155	Progression of Lower Urinary Tract Symptoms After Discontinuation of 1 Medication From 2-Year Combined Alpha-blocker and 5-Alpha-reductase Inhibitor Therapy for Benign Prostatic Hyperplasia in Men â€” A Randomized Multicenter Study. <i>Urology</i> , 2014, 83, 416-421.	0.5	19
156	The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 506-512.	0.8	19
157	Urothelial dysfunction and chronic inflammation in patients with spinal cord injuries at different levels and correlation with urodynamic findings. <i>Neurourology and Urodynamics</i> , 2015, 34, 757-762.	0.8	19
158	A real-world experience with augmentation enterocystoplastyâ€”High patient satisfaction with high complication rates. <i>Neurourology and Urodynamics</i> , 2018, 37, 744-750.	0.8	19
159	Therapeutic efficacy of low-dose (25%mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O53-O58.	0.6	19
160	International Prostatic Symptom Score â€” Voiding/Storage Subscore Ratio in Association with Total Prostatic Volume and Maximum Flow Rate Is Diagnostic of Bladder Outlet-Related Lower Urinary Tract Dysfunction in Men with Lower Urinary Tract Symptoms. <i>PLoS ONE</i> , 2013, 8, e59176.	1.1	19
161	Intravesical Botulinum Toxin A Injections Do Not Benefit Patients with Ulcer Type Interstitial Cystitis. <i>Pain Physician</i> , 2013, 2;16, 109-116.	0.3	19
162	Diagnosis and Management of Bladder Outlet Obstruction in Women. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2016, 8, 30-37.	0.6	18

#	ARTICLE	IF	CITATIONS
163	Long-term follow up and predictive factors for successful outcome of transurethral incision of the bladder neck in women with detrusor underactivity. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 807-813.	0.8	18
164	Urothelial Dysfunction and Chronic Inflammation in Diabetic Patients with Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017, 9, 151-156.	0.6	18
165	Mirabegron 25%mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. <i>Urology</i> , 2018, 117, 115-119.	0.5	18
166	Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. <i>Neurourology and Urodynamics</i> , 2018, 37, 2651-2657.	0.8	18
167	The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction. <i>Toxins</i> , 2019, 11, 728.	1.5	18
168	Prevalence of Lower Urinary Tract Symptoms in Indigenous and Non-indigenous Women in Eastern Taiwan. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 228-236.	0.8	17
169	Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. <i>Neurourology and Urodynamics</i> , 2014, 33, 331-334.	0.8	17
170	Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis" Different Mechanisms of Action of Botox on Bladder Dysfunction?. <i>Toxins</i> , 2016, 8, 75.	1.5	17
171	Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery. <i>International Urology and Nephrology</i> , 2017, 49, 1763-1770.	0.6	17
172	Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome. <i>International Neurourology Journal</i> , 2015, 19, 213-219.	0.5	16
173	Histopathological characteristics of ketamine-associated uropathy and their clinical association. <i>Neurourology and Urodynamics</i> , 2018, 37, 1764-1772.	0.8	16
174	Long-term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow-up and treatment. <i>Neurourology and Urodynamics</i> , 2019, 38, 1985-1993.	0.8	16
175	Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 66-71.	0.6	16
176	Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes among Patients with Interstitial Cystitis/Bladder Pain Syndrome: An Investigation of the European Society for the Study of Interstitial Cystitis Histopathological Classification. <i>Journal of Urology</i> , 2021, 205, 226-235.	0.2	16
177	Effects of Vaginal Trauma and Oophorectomy on the Continence Mechanism in Rats. <i>Urologia Internationalis</i> , 2002, 69, 36-41.	0.6	15
178	Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 32-41.	0.6	15
179	Endometriosis in a kidney with focal xanthogranulomatous pyelonephritis and a perinephric abscess. <i>BMC Research Notes</i> , 2015, 8, 591.	0.6	15
180	Urothelial Functional Protein and Sensory Receptors in Patients With Interstitial Cystitis/Bladder Pain Syndrome With and Without Hunner's Lesion. <i>Urology</i> , 2016, 98, 44-49.	0.5	15

#	ARTICLE	IF	CITATIONS
181	High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. <i>Medicine (United States)</i> , 2016, 95, e4962.	0.4	15
182	Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome. <i>Scientific Reports</i> , 2019, 9, 19169.	1.6	15
183	Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade 3 glomerulation might be different from other types of patients. <i>International Journal of Urology</i> , 2021, 28, 823-830.	0.5	15
184	Complication rate of neurogenic lower urinary tract dysfunction after spinal cord injury in Taiwan. <i>International Urology and Nephrology</i> , 2014, 46, 1063-1071.	0.6	14
185	Overactive Bladder Changes with Time: A 5-Year Longitudinal Followup of Changes in Overactive Bladder Symptoms, Urodynamic Studies and Urinary Nerve Growth Factor Levels. <i>Journal of Urology</i> , 2014, 192, 458-463.	0.2	14
186	Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017, 9, 27-32.	0.6	14
187	ICS teaching module: Artefacts in urodynamic pressure traces (basic module). <i>Neurourology and Urodynamics</i> , 2017, 36, 35-36.	0.8	14
188	Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder. <i>Scientific Reports</i> , 2017, 7, 43753.	1.6	14
189	Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. <i>Toxins</i> , 2018, 10, 260.	1.5	14
190	Therapeutic efficacy of biofeedback pelvic floor muscle exercise in women with dysfunctional voiding. <i>Scientific Reports</i> , 2021, 11, 13757.	1.6	14
191	Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics. <i>Scientific Reports</i> , 2021, 11, 17258.	1.6	14
192	Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. <i>PLoS ONE</i> , 2015, 10, e0134803.	1.1	14
193	Videourodynamic analysis of the relationship of Valsalva and cough leak point pressures in women with stress urinary incontinence. <i>Urology</i> , 2003, 61, 544-548.	0.5	13
194	Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxinA injection in the treatment of interstitial cystitis refractory to conventional treatment: A prospective, randomized, clinical trial. <i>Neurourology and Urodynamics</i> , 2018, 37, 1467-1473.	0.8	13
195	Role of Bladder Dysfunction in Men with Lower Urinary Tract Symptoms Refractory to Alpha-blocker Therapy: A Videourodynamic Analysis. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 32-37.	0.6	13
196	Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. <i>Geriatrics and Gerontology International</i> , 2018, 18, 1330-1333.	0.7	13
197	Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions. <i>Toxins</i> , 2019, 11, 487.	1.5	13
198	Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency. <i>Tzu Chi Medical Journal</i> , 2019, 31, 135.	0.4	13

#	ARTICLE	IF	CITATIONS
199	Long-term Outcomes of Augmentation Enterocystoplasty in Patients With End-Stage Bladder Diseases: A Single-Institute Experience Involving 102 Patients. <i>International Neurourology Journal</i> , 2017, 21, 133-138.	0.5	13
200	Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2022, 10, 1149.	1.4	13
201	Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2022, 10, 1701.	1.4	13
202	Prevalence of Lower Urinary Tract Symptoms in Male Aborigines and Non-aborigines in Eastern Taiwan. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 728-735.	0.8	12
203	Videourodynamic characteristics of interstitial cystitis/bladder pain syndrome—The role of bladder outlet dysfunction in the pathophysiology. <i>Neurourology and Urodynamics</i> , 2018, 37, 1971-1977.	0.8	12
204	Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. <i>PLoS ONE</i> , 2018, 13, e0190704.	1.1	12
205	Change of Detrusor Contractility in Patients with and without Bladder Outlet Obstruction at Ten or More Years of follow-up. <i>Scientific Reports</i> , 2019, 9, 18887.	1.6	12
206	High incidence of lower urinary tract dysfunction in women with recurrent urinary tract infections. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 33-40.	0.6	12
207	Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors. <i>International Neurourology Journal</i> , 2015, 19, 171-177.	0.5	12
208	Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction. <i>International Neurourology Journal</i> , 2020, 24, 301-312.	0.5	12
209	Prevalence and risk factors for nocturia in middle-aged and elderly people from public health centers in Taiwan. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2012, 38, 818-824.	0.7	11
210	Characteristics of Neurogenic Voiding Dysfunction in Cerebellar Stroke: A Cross-Sectional, Retrospective Video Urodynamic Study. <i>Cerebellum</i> , 2013, 12, 601-606.	1.4	11
211	Pathophysiology of interstitial cystitis/bladder pain syndrome. <i>Tzu Chi Medical Journal</i> , 2015, 27, 139-144.	0.4	11
212	Biomarkers for patients with interstitial cystitis/bladder pain syndrome. <i>Urological Science</i> , 2015, 26, 225-229.	0.2	11
213	Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 279-284.	0.8	11
214	Upregulation of neurotrophins and transforming growth factor- $\beta$ expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine-associated cystitis. <i>Neurourology and Urodynamics</i> , 2019, 38, 2303-2310.	0.8	11
215	Current management of refractory overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 109-116.	0.6	11
216	Recurrent urinary tract infection in women and overactive bladder—Is there a relationship?. <i>Tzu Chi Medical Journal</i> , 2021, 33, 13.	0.4	11

#	ARTICLE	IF	CITATIONS
217	Smaller bladder capacity and stronger bladder contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4. <i>Scientific Reports</i> , 2021, 11, 5200.	1.6	11
218	Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders. <i>Toxins</i> , 2021, 13, 359.	1.5	11
219	Possible Association between Bladder Wall Morphological Changes on Computed Tomography and Bladder-Centered Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2021, 9, 1306.	1.4	11
220	Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment. <i>Biomedicines</i> , 2022, 10, 396.	1.4	11
221	Long-Term Surgical Results of Pubovaginal Sling Procedure Using Polypropylene Mesh in the Treatment of Stress Urinary Incontinence. <i>Urologia Internationalis</i> , 2005, 74, 147-152.	0.6	10
222	Investigation of Dysfunctional Voiding in Children with Urgency Frequency Syndrome and Urinary Incontinence. <i>Urologia Internationalis</i> , 2006, 76, 72-76.	0.6	10
223	Correlation of bladder base elevation with pelvic floor hypertonicity in women with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2007, 26, 502-506.	0.8	10
224	Lower Urinary Tract Symptoms and Videoâ€urodynamic Characteristics of Women with Clinically Unsuspected Bladder Outlet Obstruction. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2013, 5, 23-27.	0.6	10
225	Role of Bladder Neck and Urethral Sphincter Dysfunction in Men with Persistent Bothersome Lower Urinary Tract Symptoms after $\alpha$ 1 Blocker Treatment. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015, 7, 143-148.	0.6	10
226	Oâ€™Leary-Sant Symptom Index Predicts the Treatment Outcome for OnabotulinumtoxinA Injections for Refractory Interstitial Cystitis/Bladder Pain Syndrome. <i>Toxins</i> , 2015, 7, 2860-2871.	1.5	10
227	Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction. <i>Tzu Chi Medical Journal</i> , 2016, 28, 89-93.	0.4	10
228	Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome. <i>Toxins</i> , 2019, 11, 676.	1.5	10
229	Efficacy and safety of mirabegron, a $\beta$ 3-adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 093-097.	0.6	10
230	Female bladder neck dysfunctionâ€”A videoâ€urodynamic diagnosis among women with voiding dysfunction. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 278-284.	0.6	10
231	Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disordersâ€”From Bench to Bedside. <i>Toxins</i> , 2020, 12, 166.	1.5	10
232	Effect of Botulinum Toxin A on Bladder Painâ€”Molecular Evidence and Animal Studies. <i>Toxins</i> , 2020, 12, 98.	1.5	10
233	Medical Attendance for Lower Urinary Tract Symptoms Is Associated with Subsequent Increased Risk of Outpatient Visits and Hospitalizations Based on a Nationwide Population-Based Database. <i>PLoS ONE</i> , 2013, 8, e57825.	1.1	10
234	Urothelial Dysfunction and Chronic Inflammation are Associated With Increased Bladder Sensation in Patients With Chronic Renal Insufficiency. <i>International Neurourology Journal</i> , 2018, 22, S46-54.	0.5	10

#	ARTICLE	IF	CITATIONS
235	Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection. <i>International Neurourology Journal</i> , 2022, 26, S57-67.	0.5	10
236	Transabdominal Ultrasound Measurement of Detrusor Wall Thickness in Patients with Overactive Bladder. <i>Tzu Chi Medical Journal</i> , 2009, 21, 129-135.	0.4	9
237	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011, 3, 2-9.	0.6	9
238	Characteristics and electrocauterization of Hunner's lesions associated with bladder pain syndrome. <i>Urological Science</i> , 2013, 24, 51-55.	0.2	9
239	Clinical Characteristic Picture and Impact of Symptoms on Quality of Life of Interstitial Cystitis Patients in Taiwan. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2014, 6, 20-25.	0.6	9
240	Long-term outcomes of anti-incontinence surgery and subsequent transvaginal sling incision for urethral obstruction. <i>International Urogynecology Journal</i> , 2019, 30, 761-766.	0.7	9
241	The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A. <i>Toxins</i> , 2020, 12, 186.	1.5	9
242	Botulinum toxin A injection in the treatment of chronic pelvic pain with hypertonic pelvic floor in women: Treatment techniques and results. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 5-12.	0.6	9
243	Urothelial health after platelet-rich plasma injection in intractable recurrent urinary tract infection: Improved cell proliferation, cytoskeleton, and barrier function protein expression. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 271-278.	0.6	9
244	Lower Levels of Urinary Nerve Growth Factor Might Predict Recurrent Urinary Tract Infections in Women. <i>International Neurourology Journal</i> , 2006, 20, 33-39.	0.5	9
245	Role of videourodynamic study in precision diagnosis and treatment for lower urinary tract dysfunction. <i>Tzu Chi Medical Journal</i> , 2020, 32, 121.	0.4	9
246	Videourodynamic precision diagnosis and treatment of lower urinary tract symptoms in women. <i>Urological Science</i> , 2021, 32, 94.	0.2	9
247	Inflammation and Barrier Function Deficits in the Bladder Urothelium of Patients with Chronic Spinal Cord Injury and Recurrent Urinary Tract Infections. <i>Biomedicines</i> , 2022, 10, 220.	1.4	9
248	The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. <i>Pain Physician</i> , 2016, 19, E581-7.	0.3	9
249	Diagnostic and prognostic value of urine biomarkers among women with dysfunctional voiding. <i>Scientific Reports</i> , 2022, 12, 6608.	1.6	9
250	Renal endometriosis mimicking an angiomyolipoma. <i>Urological Science</i> , 2013, 24, 24-26.	0.2	8
251	Management of nocturnal enuresis in Taiwan: Consensus statements of the Taiwan Enuresis expert committee. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 965-972.	0.8	8
252	Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?. <i>Toxins</i> , 2019, 11, 547.	1.5	8

#	ARTICLE	IF	CITATIONS
253	Durability of Retropubic Suburethral Sling Procedure and Predictors for Successful Treatment Outcome in Women With Stress Urinary Incontinence. <i>Urology</i> , 2019, 131, 83-88.	0.5	8
254	Changes in sensory proteins in the bladder urothelium of patients with chronic kidney disease and end-stage renal disease. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O202-O208.	0.6	8
255	Therapeutic Efficacy of Urethral Sphincteric Botulinum Toxin Injections for Female Sphincter Dysfunctions and a Search for Predictive Factors. <i>Toxins</i> , 2021, 13, 398.	1.5	8
256	Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. <i>Tzu Chi Medical Journal</i> , 2017, 29, 6.	0.4	8
257	Abnormal Sensory Protein Expression and Urothelial Dysfunction in Ketamine-Related Cystitis in Humans. <i>International Neurourology Journal</i> , 2016, 20, 197-202.	0.5	8
258	Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification. <i>Scientific Reports</i> , 2022, 12, 362.	1.6	8
259	Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?. <i>Diagnostics</i> , 2022, 12, 1093.	1.3	8
260	Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?. <i>Toxins</i> , 2022, 14, 498.	1.5	8
261	Strong Correlation Between the Overactive Bladder Symptom Score and Urgency Severity Score in Assessment of Patients With Overactive Bladder Syndrome. <i>Tzu Chi Medical Journal</i> , 2010, 22, 82-86.	0.4	7
262	Prevalence and factors associated with overactive bladder and urinary incontinence in community-dwelling Taiwanese. <i>Tzu Chi Medical Journal</i> , 2012, 24, 56-60.	0.4	7
263	5 $\alpha$ -Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 865-871.	0.8	7
264	Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder. <i>Toxins</i> , 2016, 8, 164.	1.5	7
265	Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O221-O223.	0.6	7
266	Predictive factors for recovery of voiding function after transurethral prostate surgery in men with small prostate volume and very low detrusor contractility. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 41-46.	0.6	7
267	Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions in patients with recurrent and persistent urinary tract infections. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 203-209.	0.6	7
268	Current pharmacological and surgical treatment of underactive bladder. <i>Tzu Chi Medical Journal</i> , 2017, 29, 187.	0.4	7
269	The Efficacy and Mid-term Durability of Urethral Sphincter Injections of Platelet-Rich Plasma in Treatment of Female Stress Urinary Incontinence. <i>Frontiers in Pharmacology</i> , 2022, 13, 847520.	1.6	7
270	The promise of bladder wall thickness as a useful biomarker for objective diagnosis of lower urinary tract dysfunction. <i>Tzu Chi Medical Journal</i> , 2011, 23, 1-8.	0.4	6

#	ARTICLE	IF	CITATIONS
271	Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome. <i>Tzu Chi Medical Journal</i> , 2013, 25, 13-18.	0.4	6
272	Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials. <i>Urological Science</i> , 2015, 26, 41-48.	0.2	6
273	Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. <i>Neurourology and Urodynamics</i> , 2017, 36, 338-343.	0.8	6
274	Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia. <i>Tzu Chi Medical Journal</i> , 2017, 29, 1.	0.4	6
275	Bladder dysfunction does not affect long-term success rate of the retropubic suburethral sling procedure in women with stress urinary incontinence. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O168-O173.	0.6	6
276	Obstructive patterns in videourodynamic studies predict responses of female dysfunctional voiding treated with or without urethral botulinum toxin injection: a long-term follow-up study. <i>International Urogynecology Journal</i> , 2020, 31, 2557-2564.	0.7	6
277	Will detrusor acontractility recover after medical or surgical treatment? A longitudinal long-term urodynamic follow-up. <i>Neurourology and Urodynamics</i> , 2021, 40, 228-236.	0.8	6
278	Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?. <i>Tzu Chi Medical Journal</i> , 2021, 33, 101.	0.4	6
279	Therapeutic Efficacy of Urethral Sphincter Injections of Platelet-Rich Plasma for the Treatment of Stress Urinary Incontinence due to Intrinsic Sphincter Deficiency: A Proof-of-Concept Clinical Trial. <i>International Neurourology Journal</i> , 2021, 25, 51-58.	0.5	6
280	A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection. <i>Scientific Reports</i> , 2021, 11, 5371.	1.6	6
281	Predictors of further anti-incontinence interventions or transvaginal urethrolisis after a pubovaginal sling procedure in women with and without neurologic disorders. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1464-1477.	0.8	6
282	Therapeutic Efficacy of a New Procedure for Male Urinary Incontinence Combining a Suburethral Polypropylene Mesh and Cardiovascular Patch. <i>International Neurourology Journal</i> , 2017, 21, 38-45.	0.5	6
283	Videourodynamic characteristics of lower urinary tract dysfunctions in patients with chronic brain disorders. <i>Neurourology and Urodynamics</i> , 2022, 41, 255-263.	0.8	6
284	Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction. <i>Toxins</i> , 2022, 14, 30.	1.5	6
285	Clinical Outcome of Augmentation Enterocystoplasty for Patients with Ketamine-induced Cystitis. <i>Pain Physician</i> , 2017, 20, E431-E436.	0.3	6
286	Long-Term Results of Surgical Treatment for Female Stress Urinary Incontinence. <i>Urologia Internationalis</i> , 2001, 66, 13-17.	0.6	5
287	Comparison of the Therapeutic Effects of Urethral Injections of 50 and 100 Units of Botulinum A Toxin for Voiding Dysfunction. <i>Tzu Chi Medical Journal</i> , 2007, 19, 134-138.	0.4	5
288	Editorial Comment on: Urinary Incontinence at Orgasm: Relation to Detrusor Overactivity and Treatment Efficacy. <i>European Urology</i> , 2008, 54, 915-916.	0.9	5

#	ARTICLE	IF	CITATIONS
289	Urothelial Dysfunction and Increased Suburothelial Inflammation of Urinary Bladder Are Involved in Patients with Upper Urinary Tract Urolithiasis – Clinical and Immunohistochemistry Study. PLoS ONE, 2014, 9, e110754.	1.1	5
290	Use of the International Prostate Symptom Score voiding-to-storage subscore ratio in assessing lower urinary tract symptoms. Tzu Chi Medical Journal, 2014, 26, 61-63.	0.4	5
291	Clinical guidelines for the diagnosis and management of neurogenic lower urinary tract dysfunction. Tzu Chi Medical Journal, 2014, 26, 103-113.	0.4	5
292	OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects. Drugs and Aging, 2016, 33, 1-9.	1.3	5
293	Increased bladder wall thickness is associated with severe symptoms and reduced bladder capacity in patients with bladder pain syndrome. Urological Science, 2016, 27, 263-268.	0.2	5
294	Urodynamic changes in patients with prostate cancer undergoing robotic-assisted radical prostatectomy: A comparison with laparoscopic radical prostatectomy. Urological Science, 2017, 28, 174-179.	0.2	5
295	Tailoring Medication for Lower Urinary Tract Symptoms in Men Based on International Prostate Symptom Score Voiding to Storage Ratio. Urology, 2018, 120, 30-35.	0.5	5
296	Possible predictor of early recovery on urinary continence after laparoscopic radical prostatectomy – Bladder neck level and urodynamic parameters. Journal of the Formosan Medical Association, 2019, 118, 237-243.	0.8	5
297	Surgical results in women with detrusor underactivity and stress urinary incontinence undergoing suburethral sling procedure – Predictive factors for successful outcome. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 143-149.	0.6	5
298	Clinical Outcome of Augmentation Enterocystoplasty for Patients with Ketamine-induced Cystitis. Pain Physician, 2017, 3, E431-E436.	0.3	5
299	How to choose appropriate medication for overactive bladder: Findings from the largest integrated clinical trial database analysis of mirabegron studies. Tzu Chi Medical Journal, 2022, 34, 23.	0.4	5
300	Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury. Toxins, 2022, 14, 35.	1.5	5
301	Videourodynamic results in stress urinary incontinence patients after pelvic floor muscle training. Journal of the Formosan Medical Association, 2003, 102, 23-9.	0.8	5
302	The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis. Tzu Chi Medical Journal, 2023, 35, 31.	0.4	5
303	Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome – A Comparative Study of Different Injection Number, Additives and Concentrations. Frontiers in Pharmacology, 2022, 13, 853776.	1.6	5
304	Effect of videourodynamic subtypes on treatment outcomes of female dysfunctional voiding. International Urogynecology Journal, 2022, 33, 1283-1291.	0.7	5
305	Usefulness of videourodynamic study in the decision-making of surgical intervention and bladder management for neurogenic lower urinary tract dysfunction among patients with myelomeningocele. International Urology and Nephrology, 2022, 54, 1815-1824.	0.6	5
306	Bladder Dysfunction in Older Adults: The Botulinum Toxin Option. Drugs and Aging, 2022, 39, 401-416.	1.3	5

#	ARTICLE	IF	CITATIONS
307	Recent Investigations of Urinary Nerve Growth Factor as a Biomarker for Overactive Bladder Syndrome. Korean Journal of Urology, 2009, 50, 831.	1.2	4
308	Malakoplakia of Ipsilateral Kidney, Ureter and Bladder. Tzu Chi Medical Journal, 2010, 22, 103-105.	0.4	4
309	Nerve Growth Factor Levels are Increased in Urine but Not Urothelium in Patients With Detrusor Overactivity. Tzu Chi Medical Journal, 2010, 22, 165-170.	0.4	4
310	Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder. Urological Science, 2010, 21, 38-43.	0.2	4
311	Clinical symptoms and videourodynamic findings of detrusor overactivity in women. Urological Science, 2011, 22, 116-119.	0.2	4
312	Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder. Urological Science, 2015, 26, 7-16.	0.2	4
313	Videourodynamic analysis in men with lower urinary tract symptoms: Correlation between age and prostate size with lower urinary tract dysfunction. Urological Science, 2016, 27, 21-25.	0.2	4
314	New insights into interstitial cystitis and chronic pelvic pain syndromes. Nature Reviews Urology, 2017, 14, 69-70.	1.9	4
315	Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate to severe benign prostatic hyperplasia in Asian men. International Journal of Urology, 2018, 25, 944-951.	0.5	4
316	Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder. Journal of the Formosan Medical Association, 2019, 118, 700-706.	0.8	4
317	Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O180-O185.	0.6	4
318	Repeat retropubic suburethral sling procedure is effective for recurrent female stress urinary incontinence. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O89-O92.	0.6	4
319	Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence. Tzu Chi Medical Journal, 2017, 29, 72.	0.4	4
320	Bladder Ultrastructure and Urinary Cytokine Abnormality in Patients with Recurrent Urinary Tract Infection and the Changes after Intravesical Platelet-Rich Plasma Injections. Biomedicines, 2022, 10, 245.	1.4	4
321	Interventional management and surgery of neurogenic lower urinary tract dysfunction in patients with chronic spinal cord injury: A urologist's perspective. LUTS: Lower Urinary Tract Symptoms, 2022, 14, 132-139.	0.6	4
322	Treatment outcomes of detrusor underactivity in women based on clinical and videourodynamic characteristics. International Urology and Nephrology, 2022, 54, 1215-1223.	0.6	4
323	Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan: A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study). Toxins, 2021, 13, 911.	1.5	4
324	Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma. Biomedicines, 2022, 10, 1182.	1.4	4

#	ARTICLE	IF	CITATIONS
325	Validity of the Traditional Chinese Version of the King's Health Questionnaire for Taiwanese Patients With an Overactive Bladder. <i>Urological Science</i> , 2010, 21, 180-184.	0.2	3
326	Novel treatments of interstitial cystitis/bladder pain syndrome based on pathophysiology. <i>Clinical Investigation</i> , 2012, 2, 1085-1100.	0.0	3
327	Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 29-34.	0.6	3
328	Protein expression profiling in interstitial cystitis/painful bladder syndrome: A pilot study of proteins associated with inflammation, apoptosis, and angiogenesis. <i>Urological Science</i> , 2012, 23, 107-113.	0.2	3
329	Improvement in autonomic dysreflexia after detrusor onabotulinumtoxinA injections in patients with chronic spinal cord injuries. <i>Tzu Chi Medical Journal</i> , 2012, 24, 201-204.	0.4	3
330	Reliability and Validity of the King's Health Questionnaire for Male Lower Urinary Tract Symptoms in Taiwan. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2014, 6, 11-14.	0.6	3
331	Taiwanese Continence Society clinical guidelines for diagnosis and management of neurogenic lower urinary tract dysfunction. <i>Urological Science</i> , 2014, 25, 35-41.	0.2	3
332	Clinical presentation and underlying pathophysiology of an underactive bladder. <i>Tzu Chi Medical Journal</i> , 2015, 27, 1-6.	0.4	3
333	Therapeutic effects and predictive factors for successful intravesical hyaluronic acid instillation in patients with interstitial cystitis/bladder pain syndrome. <i>Urological Science</i> , 2015, 26, 125-130.	0.2	3
334	Practical points in the medical treatment of overactive bladder and nocturia in the elderly. <i>Tzu Chi Medical Journal</i> , 2016, 28, 1-5.	0.4	3
335	The putative involvement of actin-binding proteins and cytoskeleton proteins in pathological mechanisms of ketamine cystitis—Revealed by a prospective pilot study using proteomic approaches. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600085.	0.8	3
336	Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 21-26.	0.6	3
337	Detrusor Underactivity and Bladder Outlet Procedures in Men. <i>Current Bladder Dysfunction Reports</i> , 2018, 13, 274-281.	0.2	3
338	Anxiety severity does not influence treatment outcomes in patients with interstitial cystitis/bladder pain syndrome. <i>Neurourology and Urodynamics</i> , 2019, 38, 1602-1610.	0.8	3
339	Role of poor urethral sphincter relaxation in men with voiding dysfunction refractory to $\alpha$ -blocker therapy: Clinical characteristics and predictive factors. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 8-13.	0.6	3
340	Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 125-133.	0.8	3
341	Botulinum Toxin Paves the Way for the Treatment of Functional Lower Urinary Tract Dysfunction. <i>Toxins</i> , 2020, 12, 394.	1.5	3
342	A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 108-117.	0.6	3

#	ARTICLE	IF	CITATIONS
343	High percentage of neurologic deficits in the electrophysiology study of the lower urinary tract in patients with detrusor underactivity and chronic urinary retention. <i>Neurourology and Urodynamics</i> , 2021, 40, 883-890.	0.8	3
344	Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 440-447.	0.6	3
345	Therapeutic Effects of Urethral Sphincter Botulinum Toxin A Injection on Dysfunctional Voiding with Different Videourodynamic Characteristics in Non-Neurogenic Women. <i>Toxins</i> , 2021, 13, 362.	1.5	3
346	Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice. <i>Tzu Chi Medical Journal</i> , 2022, 34, 441.	0.4	3
347	Ultrastructural changes in the underactive bladder. <i>Tzu Chi Medical Journal</i> , 2021, 33, 345.	0.4	3
348	ANATOMICAL AND FUNCTIONAL RESULTS OF PUBOVAGINAL SLING PROCEDURE USING POLYPROPYLENE MESH FOR THE TREATMENT OF STRESS URINARY INCONTINENCE. <i>Journal of Urology</i> , 2001, , 152-157.	0.2	3
349	Long-term Combination Therapy With $\alpha$ -Blockers and 5 $\alpha$ -Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication. <i>International Neurourology Journal</i> , 2016, 20, 356-362.	0.5	3
350	The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. <i>Pain Physician</i> , 2016, 4;19, E581-E587.	0.3	3
351	Long-term satisfaction and complications in women with interstitial cystitis undergoing partial cystectomy and augmentation enterocystoplasty. <i>Urological Science</i> , 2018, 29, 81.	0.2	3
352	Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients. <i>Toxins</i> , 2022, 14, 47.	1.5	3
353	Surgical outcome of male patients with chronic central nervous system disorders and voiding dysfunction due to bladder outlet obstruction. <i>International Urology and Nephrology</i> , 2022, 54, 2511-2519.	0.6	3
354	Clinical presentation, videourodynamic characteristics, and treatment outcome in men with interstitial cystitis-like lower urinary tract symptoms. <i>International Urology and Nephrology</i> , 0, , .	0.6	3
355	Videourodynamic evaluation of urge syndrome following pubovaginal sling procedure for stress urinary incontinence in women. <i>International Urogynecology Journal</i> , 2009, 20, 1253-1258.	0.7	2
356	Paraurethral striated muscular structures and pelvic floor muscles contribute to resting urethral closure pressure in rats. <i>International Urogynecology Journal</i> , 2012, 23, 1631-1636.	0.7	2
357	Do baseline urodynamic parameters affect the treatment outcome after intravesical 100 U onabotulinumtoxinA injection in patients with idiopathic detrusor overactivity?. <i>Tzu Chi Medical Journal</i> , 2012, 24, 121-126.	0.4	2
358	Pathologic mechanism of the therapeutic effect of botulinum toxin A on interstitial cystitis and painful bladder syndrome. <i>Tzu Chi Medical Journal</i> , 2012, 24, 170-177.	0.4	2
359	Videourodynamic differential diagnosis of voiding dysfunction in Taiwanese women. <i>Tzu Chi Medical Journal</i> , 2012, 24, 51-55.	0.4	2
360	The role of urodynamic study in evaluation of interstitial cystitis/painful bladder syndrome. <i>Tzu Chi Medical Journal</i> , 2013, 25, 131-134.	0.4	2

#	ARTICLE	IF	CITATIONS
361	Urodynamic characteristics of voiding dysfunction in patients with a cerebrovascular accident. <i>Urological Science</i> , 2013, 24, 21-23.	0.2	2
362	Clinical assessment and management of patients with National Institutes of Health categories IIIA and IIIB chronic prostatitis/chronic pelvic pain syndrome. <i>Tzu Chi Medical Journal</i> , 2014, 26, 151-156.	0.4	2
363	Expressions of urothelial functional proteins in idiopathic detrusor overactivity patients refractory to antimuscarinic therapy with different urodynamic characteristics. <i>Neurourology and Urodynamics</i> , 2017, 36, 1313-1319.	0.8	2
364	Individualizing medical treatment of overactive bladder. <i>Tzu Chi Medical Journal</i> , 2018, 30, 195.	0.4	2
365	Pathogenesis evidence from human and animal models of detrusor underactivity. <i>Tzu Chi Medical Journal</i> , 2022, 34, 287.	0.4	2
366	Voiding dysfunctions in patients with nonâ€Hunner's ulcer interstitial cystitis/bladder pain syndrome do not affect longâ€term treatment outcome. <i>International Journal of Clinical Practice</i> , 2021, 75, e14372.	0.8	2
367	Identifying occult bladder outlet obstruction in women with detrusor-underactivity-like urodynamic profiles. <i>Scientific Reports</i> , 2021, 11, 23242.	1.6	2
368	Clinical Correlation of Bladder Electron Microscopic Characteristics in Patients with Detrusor Underactivity of Various Etiologies. <i>Biomedicines</i> , 2022, 10, 1055.	1.4	2
369	Treatment Strategies for Neurogenic Voiding Dysfunction. <i>Tzu Chi Medical Journal</i> , 2008, 20, 35-39.	0.4	1
370	Pathophysiology of Urothelial Dysfunction in Patients with Interstitial Cystitis/Painful Bladder Pain Syndrome: Increased Apoptosis and Decreased Junctional Protein Expression in the Urothelium due to Suburothelial Inflammation. <i>Tzu Chi Medical Journal</i> , 2009, 21, 103-109.	0.4	1
371	Intravesical Botulinum Toxin Injection for Overactive Bladderâ€What We Can Learn From Previous Clinical Trials. <i>Tzu Chi Medical Journal</i> , 2009, 21, 277-284.	0.4	1
372	Recent Advances in Intravesical Treatment of Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, 2-9.	0.6	1
373	Bladder Botulinum Toxin. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S22.	0.6	1
374	Renal Oncocytoma With Specific Imaging Findings. <i>Tzu Chi Medical Journal</i> , 2010, 22, 36-38.	0.4	1
375	Therapeutic effects of transurethral incision of the bladder neck on primary bladder neck dysfunction refractory to alpha-adrenergic blockade in men. <i>Formosan Journal of Surgery</i> , 2012, 45, 78-82.	0.1	1
376	Healthâ€related quality of life in people with overactive bladder symptoms: reliability and validity of the traditional Chinese version of the Kings' Health Questionnaire. <i>International Journal of Urological Nursing</i> , 2013, 7, 154-160.	0.1	1
377	Urothelial dysfunction and sensory protein expressions in patients with urological or systemic diseases and hypersensitive bladder. <i>Urological Science</i> , 2017, 28, 128-134.	0.2	1
378	PD39-09 BLADDER FUNCTION RECOVERY AFTER TREATMENT IN MALE PATIENTS WITH DETRUSOR UNDERACTIVITY â€CLINICAL RESULTS AND PREDICTIVE FACTORS. <i>Journal of Urology</i> , 2017, 197, .	0.2	1

#	ARTICLE	IF	CITATIONS
379	Male patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O174-O179.	0.6	1
380	Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder. Tzu Chi Medical Journal, 2020, 32, 30.	0.4	1
381	Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Tzu Chi Medical Journal, 2020, 32, 5.	0.4	1
382	Neurourology, diet, and painful bladder: highlights of the 37th annual conference of the international continence society, august 20-24, 2007, rotterdam, Netherlands. Reviews in Urology, 2008, 10, 70-2.	0.9	1
383	Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study. Journal of the Formosan Medical Association, 2022, 121, 2101-2108.	0.8	1
384	Novel Biomarkers for Diagnosis and Therapeutic Assessment of Overactive Bladder: Urinary Nerve Growth Factor and Detrusor Wall Thickness. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S59.	0.6	0
385	Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography: reply to comment by Schaefer. International Urogynecology Journal, 2010, 21, 131-132.	0.7	0
386	A cyclooxygenase-2 inhibitor reduces serum prostatic-specific antigen levels in men with benign prostatic hyperplasia and lower urinary tract symptoms and helps differentiate chronic inflammation from prostate cancer. Tzu Chi Medical Journal, 2011, 23, 32-33.	0.4	0
387	Bladder Neck Dysfunction in Spinal Cord Injury. Current Bladder Dysfunction Reports, 2011, 6, 100-109.	0.2	0
388	Satisfaction and quality of life issues in patients receiving urethral botulinum toxin A injections for detrusor sphincter dyssynergia and detrusor botulinum toxin A injections for neurogenic detrusor overactivity. Tzu Chi Medical Journal, 2013, 25, 195-199.	0.4	0
389	First-line antimuscarinic monotherapy is safe and effective in men with predominant storage symptoms of the lower urinary tract. Tzu Chi Medical Journal, 2013, 25, 98-102.	0.4	0
390	Botulinum Toxin A Injections for Non-neurogenic Overactive Bladder. Current Bladder Dysfunction Reports, 2014, 9, 254-260.	0.2	0
391	The sociodemographic and clinical predictors of symptom severity in patients with refractory interstitial cystitis/bladder pain syndrome. Tzu Chi Medical Journal, 2014, 26, 79-85.	0.4	0
392	Role of serum immunoglobulin E in patients with interstitial cystitis/bladder pain syndrome. Urological Science, 2015, 26, 202-205.	0.2	0
393	Multiscale entropy analysis of surface electromyographic signals as a prognostic indicator for subtle functional impairment of urethral sphincter. , 2015, , .		0
394	Editorial Comment. Journal of Urology, 2017, 197, 1494-1495.	0.2	0
395	Botulinum toxin A treatment for lower urinary tract symptoms/benign prostatic hyperplasia. Urological Science, 2017, 28, 119-122.	0.2	0
396	Molecular Characteristics of Underactive Bladder. Current Bladder Dysfunction Reports, 2019, 14, 47-57.	0.2	0

#	ARTICLE	IF	CITATIONS
397	Intravesical OnabotulinumtoxinA Injections for Refractory Painful Bladder Syndrome. Pain Physician, 2012, 3;15, 197-202.	0.3	0
398	Current Role of Neurourologic Evaluation in Interstitial Cystitis/Bladder Pain Syndrome. , 2018, , 77-80.		0
399	A step toward precision diagnosis of interstitial cystitis. Urological Science, 2021, 32, 8.	0.2	0
400	Editorial Comment. Journal of Urology, 2022, 207, 645-645.	0.2	0